SCHEMBL2095178

SCHEMBL2095178

[CH2]CCCCCOC(=O)N(c1ccccc1)c1cc(Cl)c(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGIR P43119 11/20 0.39
PTGDR Q13258 5/20 0.37
TDP1 Q9NUW8 2/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PTGER4 P35408 2/20 0.37
PTGER3 P43115 2/20 0.37
PTGER2 P43116 2/20 0.37
PTGER1 P34995 1/20 0.37
CHRM5 P08912 3/20 0.35
CHRM1 P11229 3/20 0.35
CHRM3 P20309 3/20 0.35
CHRM2 P08172 2/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091077 0.87 TDP1 (0.47) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2097944 0.83 PTGIR (0.41) PTGIRPTGDRPTGER4PTGER3PTGER2
SCHEMBL2089905 0.81 PTGIR (0.42) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2095968 0.81 TDP1 (0.40) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2095029 0.79 ALDH1A1 (0.39) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2092943 0.78 PTGIR (0.53) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2096119 0.78 NPSR1 (0.37) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2093064 0.77 NPSR1 (0.37) PTGIRPTGDRALDH1A1HTTKMT2A
SCHEMBL2090618 0.76 PTGIR (0.39) PTGIRPTGDRTDP1ATML3MBTL1
SCHEMBL2096834 0.76 PTGIR (0.44) PTGIRPTGDRTDP1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PTGIR 1605/4885PTGDR 427/4885TDP1 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.